Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 03, 2007. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of June 30, 2007, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital: 6,020,902,833 Ordinary shares of 25p each.
- Treasury Shares: 325,549,158 Ordinary shares held in Treasury.
- Total Voting Rights: 5,695,353,675.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. It only states the current capital position as of June 30, 2007.
Guidance, Outlook, and Risks
The filing text does not provide clear values for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital and voting rights intended for shareholder calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,695,353,675) against the issued share capital minus treasury shares.
- Confirm the number of treasury shares held (325,549,158) to ensure accurate denominator calculations for disclosure thresholds.
- Note that this filing does not contain financial performance data; refer to Form 20-F or interim reports for revenue and profit metrics.